Target intelligence / Profile preview

Chromosome 22 open reading frame 46, pseudogene (C22orf46P)

Target
C22orf46P
Molecular classification
Other (pseudogene)
01

Overview

C22orf46P (chromosome 22 open reading frame 46, pseudogene) is annotated as a pseudogene in the human genome and therefore does *not* encode a functional protein product under standard genomic annotation conventions[1][4][7]. However, there is some ambiguity and potential confusion in the literature. The parent gene name "C22orf46" (sometimes also referred to as FLJ23584 or CTA-216E10.6) has been suggested by recent studies to actually encode a nuclear/nucleolar protein, called Tumor Apoptosis Associated Protein 1 (TAAP1), with roles in anti-apoptotic signaling in some cancer models[2]. This newly suggested function is for C22orf46/FLJ23584, not explicitly the pseudogene C22orf46P, which is officially annotated as a non-functional genomic element. For C22orf46P (the pseudogene, with 'P'), there is **no evidence of a therapeutic target role or interaction with drugs, nor any validated biological or disease function**[1][4][7]. There are no reported biomarkers, mechanisms of action, or safety concerns. The use of this symbol as a target is incorrect—C22orf46P itself is not considered a protein-coding target in drug discovery or therapeutics. The confusion stems from closely related names in the literature: **C22orf46** (without 'P'), whose product (FLJ23584/TAAP1) may have actual biological relevance in cancer and apoptosis[2]. Therefore, if your intent is a therapeutic target, be aware: - **C22orf46P** is a pseudogene and not a target. - **C22orf46 (TAAP1/FLJ23584)**, not the pseudogene, may encode a functional anti-apoptotic protein, but this is an emerging area and not yet standard nomenclature. If you require structured information for a therapeutic or biomarker role, you should refer to “C22orf46” (without 'P') or “Tumor Apoptosis Associated Protein 1” (TAAP1) instead[2]. **Summary:** C22orf46P is a pseudogene, not a therapeutic target; using it as a drug target is incorrect. If you are seeking biologically meaningful target information, reference C22orf46 (TAAP1) instead[1][2][4][7].

Other names
C22orf46FLJ23584CTA-216E10.6ENSG00000184208

Beyond the preview

Go deeper on Chromosome 22 open reading frame 46, pseudogene (C22orf46P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromosome 22 open reading frame 46, pseudogene (C22orf46P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call